My research interest includes: outcomes research, observational research, economic evaluations in a range of disease areas, resource allocation research, health economics of public health programs (e.g. UMV), and the economics of different disease and policy research around this.
Research around the economics of disorders of the brain and on research funding of brain research in Europe. Research in model development and economic evaluations of several health technologies in multiple disease areas.
Outcomes research based on the real world evidence. Focus on research based on electronic medical records data as well as national and disease specific registers. My research focuses on health outcomes, epidemiology and health economics.
Research in model development and economic evaluations of different health technologies in multiple disease areas. Economic research around public health initiatives such as inclusion of vaccines in UMV.
My future research areas will cover projects based on real world data and methodological developments in the design, analysis and interpretation of real world outcomes research.
The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Rheumatology (Oxford) 2004;43(9):1158-66.
Cost of disorders of the brain in Europe.
Eur J Neurology 2005;12(1):1-27.
Resource allocation to brain research in Europe (RABRE).
Eur J Neurosci 2006;24(10):2691-3.
Cost of depression in Europe.
J Ment Health Policy Econ 2006; 9(2):87-98.
Estimation of the cost of MS in Europe: extrapolations from a multinational cost study.
Mult Scler 2007;13(8):1054-64.